NZ527173A - Specific human antibodies for selective cancer therapy - Google Patents

Specific human antibodies for selective cancer therapy

Info

Publication number
NZ527173A
NZ527173A NZ527173A NZ52717301A NZ527173A NZ 527173 A NZ527173 A NZ 527173A NZ 527173 A NZ527173 A NZ 527173A NZ 52717301 A NZ52717301 A NZ 52717301A NZ 527173 A NZ527173 A NZ 527173A
Authority
NZ
New Zealand
Prior art keywords
human antibodies
cancer therapy
specific human
selective cancer
chain variable
Prior art date
Application number
NZ527173A
Other languages
English (en)
Inventor
Yocheved Hagai
Janette Lazarovits
Rachel Guy
Orly Lipschitz
Esther Szanthon
Avigdor Levanon
Daniel Plaksin
Tuvia Peretz
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of NZ527173A publication Critical patent/NZ527173A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ527173A 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy NZ527173A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
PCT/US2001/049440 WO2002059264A2 (fr) 2000-12-29 2001-12-31 Anticorps humains specifiques pour la therapie selective du cancer

Publications (1)

Publication Number Publication Date
NZ527173A true NZ527173A (en) 2006-03-31

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ527173A NZ527173A (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Country Status (15)

Country Link
EP (1) EP1353937A4 (fr)
JP (1) JP2004524023A (fr)
KR (1) KR20030091952A (fr)
CN (1) CN100374456C (fr)
AU (1) AU2002246737B2 (fr)
BR (1) BR0116763A (fr)
CA (1) CA2433227A1 (fr)
CZ (1) CZ20031983A3 (fr)
HU (1) HUP0400775A2 (fr)
IL (1) IL156690A0 (fr)
MX (1) MXPA03005944A (fr)
NZ (1) NZ527173A (fr)
PL (1) PL365758A1 (fr)
RU (1) RU2316564C2 (fr)
WO (1) WO2002059264A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678348A (zh) * 2002-07-01 2005-10-05 萨文特医药公司 用于治疗性治疗的组合物和方法
RU2006102571A (ru) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) Специфические антитела человека
KR101193797B1 (ko) 2005-04-26 2012-10-23 화이자 인코포레이티드 Ｐ-카드헤린 항체
US8580267B2 (en) 2008-12-19 2013-11-12 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
EP2933262B1 (fr) * 2010-07-09 2018-05-02 Affibody AB Polypeptides
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
DK3209685T3 (da) * 2014-10-23 2019-07-29 Singh Molecular Medicine Llc Enkeltdomæneantistoffer rettet mod intracellulære antigener
SG11201704726VA (en) * 2014-12-17 2017-07-28 Intrexon Corp Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
WO2017055635A1 (fr) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr et utilisations associées
ES2873846T3 (es) * 2015-11-19 2021-11-04 Revitope Ltd Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas
BR112019004873A2 (pt) * 2016-09-14 2019-06-11 Teneobio Inc anticorpos de ligação a cd3
AU2021377688A1 (en) * 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
KR100565883B1 (ko) * 1997-01-22 2006-03-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 응고 및 종양 치료용 조직 인자 방법 및 조성물

Also Published As

Publication number Publication date
EP1353937A2 (fr) 2003-10-22
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
WO2002059264A3 (fr) 2003-03-06
CN1551886A (zh) 2004-12-01
PL365758A1 (en) 2005-01-10
JP2004524023A (ja) 2004-08-12
RU2316564C2 (ru) 2008-02-10
BR0116763A (pt) 2004-03-09
EP1353937A4 (fr) 2005-04-13
MXPA03005944A (es) 2005-04-29
HUP0400775A2 (en) 2007-05-02
KR20030091952A (ko) 2003-12-03
WO2002059264A2 (fr) 2002-08-01
IL156690A0 (en) 2004-01-04
RU2003123100A (ru) 2005-03-10
CA2433227A1 (fr) 2002-08-01
CZ20031983A3 (cs) 2005-07-13

Similar Documents

Publication Publication Date Title
NZ527173A (en) Specific human antibodies for selective cancer therapy
ATE218890T1 (de) Bispezifische moleküle mit klinischer verwendbarkeit
AU2003278002A1 (en) Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
NZ332566A (en) Antigen binding fragments that specifically detect cancer cells
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
IL200404A (en) Couplings of 191p4d12 (b) protein-binding antibodies and their use in the treatment of cancer
WO1997046589A3 (fr) Anticorps humanises se liant au meme antigene que celui lie par l'anticorps nr-lu-13 et leur utilisation dans des procedes de preciblage
ATE265532T1 (de) Monoklonaler antikörper br110 und dessen anwendung
WO2002020039A3 (fr) Utilisation d'anticorps trifonctionnels bispecifiques et trispecifiques dans le traitement d'ascites malignes
HK1072272A1 (en) Anti-ccr5 antibody
IL162117A0 (en) Humanized collagen antibodies and methods utilizing the same
IL172242A0 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
EP1881064A3 (fr) Anticorps monoclonaux HCV-anti-cýur
DK1479696T3 (da) Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi
EP1581096A3 (fr) Antigene pipa et anticorps de liaison a celui-ci
AU6171894A (en) Preparation of photoprotein conjugates and methods of use thereof
AU3587599A (en) Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
AU2003226127A1 (en) Antibody libraries
WO2004050849A3 (fr) Immunotoxine recombinante et son utilisation dans le traitement de tumeurs
WO2003072727A3 (fr) Anticorps monoclonaux specifiques d'egfrviii, ribozymes d'egfrviii et utilisations en detection, traitement ou prevention de cancer associe a l'egfrviii
BG102513A (en) Method for the diagnostics and the treatment of flat cellular cancer
WO2005049652A3 (fr) Procede de generation in vitro d'une diversite d'anticorps
NO20005833D0 (no) Humaniserte antistoffer som gjenkjenner verotoksin II og cellelinje som produserer det samme
AU6167296A (en) Monoclonal antibody fragment to human ovarian cancers

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed